The Biotech Inflection Point Most Investors Miss

There is a moment in biotech when everything changes.

It’s not when a company is talking about a new idea. It’s not when they are years away from results.

It’s when real human data starts to show up and regulators begin paying attention.

That is where Creative Medical Technology Holdings (NASDAQ: CELZ) sits today.

After years of development, the company is no longer just a concept. It now has clinical data, a defined regulatory pathway, and a lead therapy moving toward a major data readout in 2026.

That shift, from early-stage science to real-world validation, is usually where revaluations begin.

A Massive Problem That Still Has No Real Fix

Chronic lower back pain is one of the most common and frustrating medical conditions in the world.

Millions of people deal with it daily, and for many, it becomes a long-term issue that never truly gets resolved.

The root of the problem is often something called degenerative disc disease. The simplest way to understand it is this: the discs in your spine, which act like cushions between your bones, start to break down over time. They lose structure, hydration, and function. That leads to pain, stiffness, and reduced mobility.

Most treatments don’t actually fix this damage.

Instead, they try to manage the symptoms. Patients are often given injections to reduce inflammation, prescribed pain medication, or eventually pushed toward surgery. These approaches can help temporarily, but they don’t repair the disc itself.

That gap, between treating pain and actually repairing the damage, is where Creative Medical Technology Holdings (NASDAQ: CELZ) is focused.

CELZ-201: A Different Way to Treat Back Pain

The company’s lead therapy, CELZ-201, is built around a very different idea.

Instead of masking pain, it is designed to help the body repair damaged tissue.

This is what’s known as a cell therapy. Rather than using traditional drugs, the treatment uses living cells to support healing. In this case, the cells come from perinatal tissue, which is tissue associated with birth, like umbilical-derived material. These cells are known for their ability to reduce inflammation and promote repair.

Another important detail is that the therapy is allogeneic, which simply means the cells come from a donor and can be used off-the-shelf. Patients don’t need to go through a complicated process of harvesting their own cells.

The treatment is delivered through a targeted injection near the damaged area, guided by imaging. There is no major surgery involved.

So instead of removing tissue, fusing the spine, or suppressing pain signals, the goal is to improve the condition of the disc itself.

If that approach proves effective at scale, it represents a meaningful shift in how this condition is treated.

The Data Is Starting to Back It Up

This is where the story becomes more than just a theory.

Creative Medical Technology Holdings (NASDAQ: CELZ) has been running a clinical study called the ADAPT trial. This is a structured test where patients receive the therapy and their outcomes are measured over time.

The company has already released interim results, which are early snapshots of how patients are responding before the full dataset is finalized.

The results showed two things that matter most in this type of condition.

First, patients experienced a reduction in pain. Second, they showed improvement in their ability to function day to day.

One of the key ways this is measured is through something called the Oswestry Disability Index. It is essentially a standardized scoring system that tracks how much back pain interferes with normal life. When that score improves, it means patients are moving better and living more normally.

So far, the data suggests that patients treated with CELZ-201 are seeing meaningful improvements.

Equally important, the safety profile has remained clean, with no major treatment-related concerns reported in the study so far.

The full results are expected in 2026, and that will be a defining moment for the program.

Why This Moment Matters

There are a few things happening at the same time that make this stage important for Creative Medical Technology Holdings (NASDAQ: CELZ).

The company has received FDA Fast Track designation, which is given to therapies that address serious conditions with limited treatment options. In simple terms, it allows the company to work more closely with regulators and potentially move faster through the approval process.

At the same time, the technology is not limited to one condition. The same underlying platform is being explored in other areas like diabetes and heart-related diseases, which opens the door to multiple large markets if the science continues to hold.

Most importantly, the company has moved past the stage where everything depends on assumptions. It now has real patient data, a defined clinical pathway, and upcoming milestones that the market can measure.

That transition, from idea to evidence, is what tends to change how investors view these companies.

The Bottom Line

Biotech stories are always high risk, especially at this stage.

But they also tend to follow a pattern.

The biggest moves often happen when a company shifts from early development into validated clinical progress.

That is the transition Creative Medical Technology Holdings (NASDAQ: CELZ) is now making.

It has a large, well-defined market, a different approach to treatment, early data showing real signals, and a clear set of catalysts ahead.

The next phase will be driven by data.

And in biotech, that is what ultimately determines everything.

DISCLAIMER: SPONSORED CONTENT AND THIRD-PARTY DISTRIBUTION

This communication constitutes sponsored content regarding Creative Medical Technology Holdings | NYSE American: CELZ (the "Issuer") and is provided strictly for informational and educational purposes only. This communication does not constitute financial advice, investment advice, or a recommendation to buy, sell, or hold any securities.

This content has been prepared and disseminated by Matt Allen Enterprises (the "Publisher"). The Publisher, including its officers, directors, owners, employees, affiliates, and control persons, has been compensated to produce and distribute this communication. In accordance with Section 17(b) of the Securities Act of 1933, as amended, the Publisher discloses that it has received compensation in the amount of $500 from Creative Medical Technology Holdings to publicly disseminate information about the Issuer. The expected publication period of this campaign is from April 8, 2026 through April 8, 2026, unless extended or modified.

Role of AION Promotions, Inc.

AION Promotions, Inc. ("AION") acts solely as a marketing intermediary and administrative service provider. AION does not create, produce, review, approve, endorse, or control any content distributed by the Publisher or any third-party service providers, including influencers, social media accounts, newsletters, SMS distribution platforms, or online communities.

All content, statements, representations, and opinions expressed are the sole responsibility of the Publisher and/or the Issuer. AION does not act as a publisher, promoter, broker-dealer, investment adviser, or financial analyst. AION does not provide investment advice or recommendations of any kind.

To the fullest extent permitted by law, AION expressly disclaims any and all liability for the accuracy, completeness, reliability, or regulatory compliance of any content distributed in connection with this campaign.

Content Accuracy and Sources

The Publisher does not independently verify, and expressly disclaims any obligation to verify, the accuracy, completeness, or reliability of any information presented. The content may be derived from publicly available sources, third-party materials, or information supplied directly or indirectly by the Issuer or its representatives. Accordingly, the Publisher makes no representations or warranties regarding the accuracy, completeness, or timeliness of the information and assumes no liability for any errors or omissions.

No Investment Advice

The Publisher is not a registered broker-dealer, investment adviser, or financial analyst. Any opinions expressed are general in nature and are not tailored to any specific individual or investment objective. Readers should not rely on this communication as the basis for any investment decision.

Risk Disclosure

Investing in securities involves substantial risk, including the possible loss of principal. Any references to past performance, price movements, or percentage gains are not indicative of future results and may reflect selective or non-standardized time periods.

Conflicts of Interest

The Publisher, the Issuer, and their respective affiliates, partners, or clients may buy, sell, or hold positions in the Issuer's securities before, during, or after the dissemination of this communication. Such activity may create conflicts of interest and may influence the market price or trading volume of the Issuer's securities. There is no obligation to disclose specific positions, and readers should assume that such activity may occur.

Forward-Looking Statements

This communication may contain forward-looking statements within the meaning of applicable securities laws. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially. Words such as "anticipates," "expects," "intends," "plans," "believes," or similar expressions identify such statements. Neither the Publisher nor AION undertakes any obligation to update or revise forward-looking statements except as required by law.

Third-Party Distribution and Influencers

This campaign may involve third-party service providers, including but not limited to influencers, digital marketers, social media platforms, newsletters, SMS distribution services, and online communities. These third parties operate independently and are solely responsible for their content and compliance with applicable laws and regulations. AION does not control, supervise, or assume responsibility for third-party communications.

Due Diligence

Readers are strongly encouraged to conduct their own independent due diligence prior to making any investment decision, including reviewing filings with the U.S. Securities and Exchange Commission (www.sec.gov), the Financial Industry Regulatory Authority (www.finra.org), and OTC Markets (www.otcmarkets.com), where applicable. Consultation with a licensed financial advisor, attorney, or other qualified professional is strongly recommended.

Limitation of Liability

By accessing or reviewing this communication, you acknowledge that you are solely responsible for your own investment decisions. To the fullest extent permitted by law, you agree to hold harmless the Publisher, AION Promotions, Inc., and their respective affiliates, officers, directors, employees, and agents from any and all direct or indirect losses, damages, or liabilities arising from your use of or reliance upon this communication.